CA2325930A1 - Medicament pour prevenir et traiter la dysfonction sexuelle - Google Patents
Medicament pour prevenir et traiter la dysfonction sexuelle Download PDFInfo
- Publication number
- CA2325930A1 CA2325930A1 CA002325930A CA2325930A CA2325930A1 CA 2325930 A1 CA2325930 A1 CA 2325930A1 CA 002325930 A CA002325930 A CA 002325930A CA 2325930 A CA2325930 A CA 2325930A CA 2325930 A1 CA2325930 A1 CA 2325930A1
- Authority
- CA
- Canada
- Prior art keywords
- medicament
- sexual dysfunction
- treatment
- prevention
- female sexual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title claims abstract description 150
- 230000002265 prevention Effects 0.000 title claims abstract description 65
- 201000001880 Sexual dysfunction Diseases 0.000 title abstract description 36
- 231100000872 sexual dysfunction Toxicity 0.000 title abstract description 36
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims abstract description 61
- 229960001789 papaverine Drugs 0.000 claims abstract description 58
- 206010057671 Female sexual dysfunction Diseases 0.000 claims abstract description 55
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 claims abstract description 52
- 229960002497 nicorandil Drugs 0.000 claims abstract description 52
- 210000003029 clitoris Anatomy 0.000 claims abstract description 42
- 210000001215 vagina Anatomy 0.000 claims abstract description 34
- IVVNZDGDKPTYHK-JTQLQIEISA-N 1-cyano-2-[(2s)-3,3-dimethylbutan-2-yl]-3-pyridin-4-ylguanidine Chemical compound CC(C)(C)[C@H](C)N=C(NC#N)NC1=CC=NC=C1 IVVNZDGDKPTYHK-JTQLQIEISA-N 0.000 claims abstract description 24
- 229960002310 pinacidil Drugs 0.000 claims abstract description 24
- TVZCRIROJQEVOT-CABCVRRESA-N Cromakalim Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C#N)CCCC1=O TVZCRIROJQEVOT-CABCVRRESA-N 0.000 claims abstract description 22
- 229950004210 cromakalim Drugs 0.000 claims abstract description 22
- 230000000699 topical effect Effects 0.000 claims abstract description 12
- 206010057672 Male sexual dysfunction Diseases 0.000 claims description 27
- 210000003899 penis Anatomy 0.000 claims description 26
- 239000004480 active ingredient Substances 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 20
- 230000000982 vasogenic effect Effects 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 9
- 239000006210 lotion Substances 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 8
- -1 patch Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 7
- 239000007943 implant Substances 0.000 claims description 5
- 239000000829 suppository Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 27
- 230000017531 blood circulation Effects 0.000 abstract description 25
- 230000001965 increasing effect Effects 0.000 abstract description 18
- 230000001568 sexual effect Effects 0.000 abstract description 18
- 108091006146 Channels Proteins 0.000 abstract description 11
- 230000037007 arousal Effects 0.000 abstract description 9
- 239000004036 potassium channel stimulating agent Substances 0.000 abstract description 8
- 210000000056 organ Anatomy 0.000 abstract description 4
- 230000009885 systemic effect Effects 0.000 abstract description 4
- 230000028327 secretion Effects 0.000 abstract description 3
- 230000003028 elevating effect Effects 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000002460 smooth muscle Anatomy 0.000 description 35
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 32
- 229960003632 minoxidil Drugs 0.000 description 32
- 229940079593 drug Drugs 0.000 description 30
- 230000004044 response Effects 0.000 description 19
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 18
- 210000005226 corpus cavernosum Anatomy 0.000 description 16
- 230000007423 decrease Effects 0.000 description 15
- 102000004257 Potassium Channel Human genes 0.000 description 14
- 229940088597 hormone Drugs 0.000 description 14
- 239000005556 hormone Substances 0.000 description 14
- 108020001213 potassium channel Proteins 0.000 description 14
- 239000002858 neurotransmitter agent Substances 0.000 description 13
- 230000002040 relaxant effect Effects 0.000 description 13
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 12
- 229960004373 acetylcholine Drugs 0.000 description 12
- 102000016924 KATP Channels Human genes 0.000 description 11
- 108010053914 KATP Channels Proteins 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 210000001367 artery Anatomy 0.000 description 10
- 230000008602 contraction Effects 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 201000001881 impotence Diseases 0.000 description 9
- 102000016469 Large-Conductance Calcium-Activated Potassium Channels Human genes 0.000 description 8
- 108010092555 Large-Conductance Calcium-Activated Potassium Channels Proteins 0.000 description 8
- 210000005036 nerve Anatomy 0.000 description 8
- 108090000312 Calcium Channels Proteins 0.000 description 7
- 102000003922 Calcium Channels Human genes 0.000 description 7
- 208000010228 Erectile Dysfunction Diseases 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 7
- 229960001802 phenylephrine Drugs 0.000 description 7
- 229940127315 Potassium Channel Openers Drugs 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000004648 relaxation of smooth muscle Effects 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 5
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- 229930064664 L-arginine Natural products 0.000 description 5
- 235000014852 L-arginine Nutrition 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- FQYUMYWMJTYZTK-UHFFFAOYSA-N Phenyl glycidyl ether Chemical compound C1OC1COC1=CC=CC=C1 FQYUMYWMJTYZTK-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 4
- 101001077186 Androctonus mauritanicus mauritanicus Potassium channel toxin alpha-KTx 3.1 Proteins 0.000 description 4
- 101710126338 Apamin Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 4
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000003205 diastolic effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000001856 erectile effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004392 genitalia Anatomy 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 4
- VRARWAGTAUYUOO-UHFFFAOYSA-N kaliotoxin Chemical compound N1C(=O)C(CCCNC(N)=N)NC(=O)C(CCSC)NC(=O)CNC(=O)C(C)NC(=O)C(CC(O)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)C2CCCN2C(=O)C(CCCCN)NC(=O)C(CC(C)C)NC2=O)CSSCC(C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(O)=O)NC(=O)C(CC=3N=CNC=3)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(CCCNC(N)=N)NC(=O)C(CC(N)=O)NC(=O)C(CCSC)NC3=O)CSSCC2NC(=O)C(CCC(N)=O)NC(=O)C2CCCN2C(=O)C(CO)NC(=O)CNC(=O)C(CO)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)CN)C(C)C)C(C)CC)CSSCC3NC(=O)C(CCCCN)NC(=O)CNC(=O)C1CC1=CC=CC=C1 VRARWAGTAUYUOO-UHFFFAOYSA-N 0.000 description 4
- 230000009245 menopause Effects 0.000 description 4
- YVIIHEKJCKCXOB-STYWVVQQSA-N molport-023-276-178 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(N[C@@H](CSSC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N2)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)=O)CC(C)C)[C@@H](C)O)C(N)=O)C1=CNC=N1 YVIIHEKJCKCXOB-STYWVVQQSA-N 0.000 description 4
- 230000037384 skin absorption Effects 0.000 description 4
- 231100000274 skin absorption Toxicity 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 3
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 description 3
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 description 3
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 3
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229960004979 fampridine Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 230000035946 sexual desire Effects 0.000 description 3
- 230000036299 sexual function Effects 0.000 description 3
- 230000036332 sexual response Effects 0.000 description 3
- 239000000050 smooth muscle relaxant Substances 0.000 description 3
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 101710151321 Melanostatin Proteins 0.000 description 2
- 102400000064 Neuropeptide Y Human genes 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229960000711 alprostadil Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009460 calcium influx Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009552 doppler ultrasonography Methods 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 2
- 239000003450 potassium channel blocker Substances 0.000 description 2
- FCTRVTQZOUKUIV-MCDZGGTQSA-M potassium;[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound [K+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O FCTRVTQZOUKUIV-MCDZGGTQSA-M 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 description 2
- 208000015891 sexual disease Diseases 0.000 description 2
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229940094720 viagra Drugs 0.000 description 2
- OIICUUGPVAEJSH-UHFFFAOYSA-M (2-bromophenyl)methyl-ethyl-dimethylazanium;bromide Chemical compound [Br-].CC[N+](C)(C)CC1=CC=CC=C1Br OIICUUGPVAEJSH-UHFFFAOYSA-M 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 102100038518 Calcitonin Human genes 0.000 description 1
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
- 108010023798 Charybdotoxin Proteins 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 208000021473 Ejaculation disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Chemical class 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000006406 biphasic response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- CNVQLPPZGABUCM-LIGYZCPXSA-N ctx toxin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@@H](C(N[C@@H](CC=4C5=CC=CC=C5NC=4)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3NC=NC=3)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N2)C(C)C)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC1=O)=O)CCSC)C(C)C)[C@@H](C)O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 CNVQLPPZGABUCM-LIGYZCPXSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000005225 erectile tissue Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 208000017020 hypoactive sexual desire disease Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000001129 nonadrenergic effect Effects 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940125422 potassium channel blocker Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000033904 relaxation of vascular smooth muscle Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000036259 sexual stimuli Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 206010046947 vaginismus Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 102000008396 voltage-gated potassium channel activity proteins Human genes 0.000 description 1
- 108040002559 voltage-gated potassium channel activity proteins Proteins 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
- B22D41/00—Casting melt-holding vessels, e.g. ladles, tundishes, cups or the like
- B22D41/001—Casting melt-holding vessels, e.g. ladles, tundishes, cups or the like devices for cleaning ladles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
- B22D43/00—Mechanical cleaning, e.g. skimming of molten metals
Landscapes
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020000004428A KR20010076961A (ko) | 2000-01-29 | 2000-01-29 | 성기능장애 예방 및 치료용 약제 |
| KR2000-4428 | 2000-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2325930A1 true CA2325930A1 (fr) | 2001-07-29 |
Family
ID=19642703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002325930A Abandoned CA2325930A1 (fr) | 2000-01-29 | 2000-11-14 | Medicament pour prevenir et traiter la dysfonction sexuelle |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR20010076961A (fr) |
| AR (1) | AR026506A1 (fr) |
| BR (1) | BR0005785A (fr) |
| CA (1) | CA2325930A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002069906A3 (fr) * | 2001-03-06 | 2003-11-20 | Cellegy Pharma Inc | Composes et procedes pour le traitement de desordres urogenitaux |
| EP1447450A1 (fr) * | 2001-09-27 | 2004-08-18 | Dnavec Research Inc. | Procede de regulation de l'expression d'un gene porte par un vecteur viral |
| WO2005013962A1 (fr) * | 2003-07-30 | 2005-02-17 | Laboratorios Del Dr. Esteve S.A. | Combinaison de substance active comprenant un compose de 2,5-dihydroxybenzene sulfonique et un modulateur de canal d'ion potassium |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010016165A (ko) * | 2000-11-16 | 2001-03-05 | 정순학 | 성기능 장애 치료를 위한 피부에 적용하는 제제 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0618798T3 (da) * | 1991-12-23 | 1997-09-22 | Upjohn Co | Pyridylguanidinforbindelser til behandling af erektiv dysfunktion. |
| NZ305560A (en) * | 1995-03-14 | 1998-11-25 | Vivus Inc | Method for preventing erectile dysfunction by administering vasoactive agent, particularly a prostaglandin, kit therefor |
| KR100287626B1 (ko) * | 1995-11-24 | 2001-04-16 | 김윤 | 발기부전치료용약물조성및경피투여제형 |
| US6150338A (en) * | 1997-02-13 | 2000-11-21 | Albert Einstein College Of Medicine Of Yeshiva University | Gene therapy for alleviating erectile dysfunction |
| US6214849B1 (en) * | 1999-04-29 | 2001-04-10 | Lupin Laboratories Limited | Use of nicorandil in treatment of sexual dysfunction or for enhancement of sexual function in mammals including humans |
-
2000
- 2000-01-29 KR KR1020000004428A patent/KR20010076961A/ko not_active Application Discontinuation
- 2000-11-14 CA CA002325930A patent/CA2325930A1/fr not_active Abandoned
- 2000-11-16 AR ARP000106057A patent/AR026506A1/es unknown
- 2000-11-17 BR BR0005785-1A patent/BR0005785A/pt not_active Application Discontinuation
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002069906A3 (fr) * | 2001-03-06 | 2003-11-20 | Cellegy Pharma Inc | Composes et procedes pour le traitement de desordres urogenitaux |
| US6987129B2 (en) | 2001-03-06 | 2006-01-17 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
| EP1447450A1 (fr) * | 2001-09-27 | 2004-08-18 | Dnavec Research Inc. | Procede de regulation de l'expression d'un gene porte par un vecteur viral |
| EP1447450A4 (fr) * | 2001-09-27 | 2005-02-16 | Dnavec Research Inc | Procede de regulation de l'expression d'un gene porte par un vecteur viral |
| WO2005013962A1 (fr) * | 2003-07-30 | 2005-02-17 | Laboratorios Del Dr. Esteve S.A. | Combinaison de substance active comprenant un compose de 2,5-dihydroxybenzene sulfonique et un modulateur de canal d'ion potassium |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010076961A (ko) | 2001-08-17 |
| BR0005785A (pt) | 2001-11-27 |
| AR026506A1 (es) | 2003-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69415535T2 (de) | Verfahren zur regulierung der sexuellen reaktion beim menschen | |
| DE69917066T2 (de) | Zusammensetzungen und methoden zur verbesserung von sexuellen funktionsstörungen bei frauen | |
| EP0814800B1 (fr) | Creme pour application locale a base d'eau contenant de la nitroglycerine, et son procede de preparation et d'utilisation | |
| JP3211892B2 (ja) | 肛門疾患を治療する窒素酸化物供与体及び方法 | |
| DE69604762T2 (de) | Verfahren und formulierungen zur modulation der sexualreaktion beim menschen | |
| DE60121841T2 (de) | Zusammensetzungen und verfahren zur behandlung von zuständen, die auf eine testosteronerhöhung ansprechen | |
| DE60112102T2 (de) | Kombination aus einem no-donor und einem antioxidans zur behandlung sexueller störungen | |
| US6589990B1 (en) | Methods and compositions for misoprostol compound treatment of erectile dysfunction | |
| KR20010071283A (ko) | 유기 질산염 또는 유기 이질산염을 함유하는 발기부전치료용 조성물 | |
| US20180318398A1 (en) | Methods and compositions using ampk activators for pharmacological prevention of chronic pain | |
| US6803060B2 (en) | Composition to boost libido | |
| IT9009007A1 (it) | 2, 4-diamino-6 piperidino pirimidina-3 ossido topico sul glande nel trattamento delle impotenze erettili | |
| CA2325930A1 (fr) | Medicament pour prevenir et traiter la dysfonction sexuelle | |
| Benkert et al. | Sexual impotence: a double-blind study of LHRH nasal spray versus placebo | |
| WO2011130608A9 (fr) | Procédés et compositions pour stimuler l'excitation sexuelle chez la femme et traiter un trouble sexuel chez la femme | |
| WO2002051426A2 (fr) | Compositions et methodes permettant de traiter des dysfonctions sexuelles, d'ameliorer l'activite sexuelle et d'augmenter les niveaux de testosterone, et d'ameliorer la force et la masse musculaires | |
| US20070042060A1 (en) | Methods to treat one or all of the defined etiologies of female sexual Dysfunction | |
| AU5100300A (en) | Use of a vitamin combination for the treatment of pruritus and non-infective disorders involving itching and/or inflammation | |
| US6214849B1 (en) | Use of nicorandil in treatment of sexual dysfunction or for enhancement of sexual function in mammals including humans | |
| MXPA00011386A (en) | A medicament for prevention and treatment of sexual dysfunction | |
| WO2005049053A1 (fr) | Composition comprenant un compose de magnesium et/ou un sel de magnesium ameliorant les dysfonctionnements sexuels | |
| US20050260253A1 (en) | Transmucosal gel formulations | |
| US20240335371A1 (en) | Magnesium sulfate and forskolin for treatment of sexual disorders and benign prostatic hyperplasia | |
| US10117863B2 (en) | Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction | |
| CA2214418C (fr) | Creme pour application locale a base d'eau contenant de la nitroglycerine, et son procede de preparation et d'utilisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |